比阿培南治疗呼吸系统和泌尿系统细菌性感染疗效和安全性的Meta分析
发布时间：2018-08-13 08:14
【摘要】：目的系统评价比阿培南治疗呼吸系统和泌尿系统细菌性感染的临床疗效和安全性。方法通过PubMed数据库、ELSEVIER数据库、相关期刊论文、万方数据库,检索比阿培南治疗呼吸系统和泌尿系统细菌性感染的临床随机对照试验文献,采用Rev Man 5.1版统计分析软件进行Meta分析,采用GRADE profiler 3.6版软件对证据质量进行评价分级。结果共有9篇文献符合纳入标准,全部文献共有患者1 397例,在总有效率[RR=1.04,95%CI(0.98,1.10),P=0.19]、细菌清除率[RR=1.02,95%CI(0.97,1.07),P=0.39]、呼吸系统细菌性感染有效率[RR=1.04,95%CI(0.97,1.11),P=0.26]、泌尿系统细菌性感染有效率[RR=0.98,95%CI(0.88,1.09),P=0.74]、总不良反应发生率[RR=0.83,95%CI(0.60,1.15),P=0.26]及各不良反应发生率方面,治疗组(比阿培南)与对照组(亚胺培南/西司他丁钠、美罗培南或其他碳青霉烯类抗菌药物)均差异无统计学意义(P0.05)。GRADE系统评价结果显示,总不良反应发生率和各不良反应发生率的证据水平为中等,其余各结局指标均为低级。结论基于当前的临床证据,比阿培南治疗各种敏感菌所引起的呼吸系统和泌尿系统细菌性感染的有效性和安全性与美罗培南和亚胺培南/西司他丁相当。
[Abstract]:Objective to evaluate the efficacy and safety of Biapenem in the treatment of bacterial infections of respiratory and urinary systems. Methods the clinical randomized controlled trials of Biapenem in the treatment of bacterial infection of respiratory system and urinary system were searched by PubMed database, Chinese periodical full-text database and Wanfang database. The statistical analysis software of Rev Man 5.1 was used for Meta analysis, and the software GRADE profiler 3.6 was used to evaluate the quality of evidence. Results A total of 9 articles met the inclusion criteria, and 1,397 patients were included in all the literature. The total effective rate [RRN 1.04C _ (95) CI (0.981.10) P _ (0.19)], the bacterial clearance rate [RRN _ 1.02C _ (95) CI (0.971.07) P _ (0.39)], the effective rate of respiratory bacterial infection [(R _ (1.04) ~ (95) CI (0.971.11) P _ (0.26)], the effective rate of urinary system infection [RRN _ (0.9895) CI (0.88 卤1.09) P _ (0.74)], the incidence of total adverse reactions [RR0.83C _ (95) CI (0.601.15)] and the incidence of adverse reactions were observed. There was no significant difference between the treatment group (Biapenem) and the control group (imipenem / cilastatin sodium, meropenem or other carbapenem antibiotics) (P0.05). The incidence of total adverse reactions and the incidence of adverse reactions were moderate, and the other outcome indicators were low. Conclusion based on current clinical evidence, Biapenem is as effective and safe as meropenem and imipenem / cilastatin in the treatment of bacterial infections of respiratory and urinary systems caused by various sensitive bacteria.
【作者单位】： 郑州大学第一附属医院药学部;
【分类号】：R56;R691.3
本文编号：2180399
[Abstract]:Objective to evaluate the efficacy and safety of Biapenem in the treatment of bacterial infections of respiratory and urinary systems. Methods the clinical randomized controlled trials of Biapenem in the treatment of bacterial infection of respiratory system and urinary system were searched by PubMed database, Chinese periodical full-text database and Wanfang database. The statistical analysis software of Rev Man 5.1 was used for Meta analysis, and the software GRADE profiler 3.6 was used to evaluate the quality of evidence. Results A total of 9 articles met the inclusion criteria, and 1,397 patients were included in all the literature. The total effective rate [RRN 1.04C _ (95) CI (0.981.10) P _ (0.19)], the bacterial clearance rate [RRN _ 1.02C _ (95) CI (0.971.07) P _ (0.39)], the effective rate of respiratory bacterial infection [(R _ (1.04) ~ (95) CI (0.971.11) P _ (0.26)], the effective rate of urinary system infection [RRN _ (0.9895) CI (0.88 卤1.09) P _ (0.74)], the incidence of total adverse reactions [RR0.83C _ (95) CI (0.601.15)] and the incidence of adverse reactions were observed. There was no significant difference between the treatment group (Biapenem) and the control group (imipenem / cilastatin sodium, meropenem or other carbapenem antibiotics) (P0.05). The incidence of total adverse reactions and the incidence of adverse reactions were moderate, and the other outcome indicators were low. Conclusion based on current clinical evidence, Biapenem is as effective and safe as meropenem and imipenem / cilastatin in the treatment of bacterial infections of respiratory and urinary systems caused by various sensitive bacteria.
【作者单位】： 郑州大学第一附属医院药学部;
【分类号】：R56;R691.3
【相似文献】
相关期刊论文 前9条
1 胡绳;肖贞良;田坤;连亨宁;;比阿培南治疗全耐药鲍曼不动杆菌肺炎体会[J];现代中西医结合杂志;2010年31期
2 覃永;龙胜泽;;国产比阿培南治疗支气管扩张症合并细菌感染的疗效观察[J];重庆医学;2011年16期
3 王丹凤;唐良法;;比阿培南与亚胺培南/西司他丁治疗下呼吸道感染疗效对比[J];山东医药;2011年29期
4 阎晓路;董元洪;王晶;;国产比阿培南治疗中度至重度呼吸道感染疗效观察[J];世界临床药物;2010年03期
5 惠复新;吴艳;汪家坤;;比阿培南治疗重症肺炎32例疗效观察[J];山东医药;2010年39期
6 杨帆;赵旭;吴菊芳;周新;修清玉;施毅;沈策;刘荣玉;张伯科;钟玲;陈楠;倪兆慧;苏炳华;吴n\;张婴元;;比阿培南治疗细菌性肺炎和尿路感染的多中心随机对照临床试验[J];中国感染与化疗杂志;2007年02期
7 吴艳;惠复新;范晓东;汪家坤;孙华;;比阿培南治疗慢性阻塞性肺疾病急性加重期临床评价[J];山东大学学报(医学版);2010年09期
8 许蕾;王笑歌;李方治;刘朔;陈东红;李晶;;国产比阿培南治疗重度老年院内获得性肺炎61例[J];中国老年学杂志;2011年19期
9 高军军;常璇;袁军;;高龄老年肺部感染应用比阿培南治疗合并红皮病1例[J];中华保健医学杂志;2010年05期
，本文编号：2180399
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2180399.html
最近更新
教材专著
